What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Immune system
Carl H. June spends much of his time researching Immunology, Antigen, T cell, Chimeric antigen receptor and Immunotherapy.
His studies in Immunology integrate themes in fields like Cytotoxic T cell, Cancer and Cell therapy.
The study incorporates disciplines such as Antibody, B cell, Receptor, Chimeric Antigen Receptor T-Cell Therapy and T-cell receptor in addition to Antigen.
He works on T cell which deals in particular with CD28.
The concepts of his Chimeric antigen receptor study are interwoven with issues in Cancer research and Leukemia.
His work carried out in the field of Immunotherapy brings together such families of science as Acquired immune system and Tumor microenvironment.
His most cited work include:
- Chimeric antigen receptor T cells for sustained remissions in leukemia. (2837 citations)
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (2518 citations)
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (2270 citations)
What are the main themes of his work throughout his whole career to date?
Carl H. June focuses on Immunology, T cell, Chimeric antigen receptor, Cancer research and Antigen.
His Immunology research integrates issues from Cytotoxic T cell and Internal medicine.
His T cell research incorporates themes from Molecular biology, CD8 and Cell biology.
His Chimeric antigen receptor course of study focuses on CD19 and B cell.
His Cancer research study combines topics in areas such as Car t cells and In vivo.
His Antigen study combines topics from a wide range of disciplines, such as Receptor and Antibody.
He most often published in these fields:
- Immunology (43.09%)
- T cell (36.69%)
- Chimeric antigen receptor (28.07%)
What were the highlights of his more recent work (between 2015-2021)?
- Chimeric antigen receptor (28.07%)
- Cancer research (23.54%)
- T cell (36.69%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Chimeric antigen receptor, Cancer research, T cell, Immunology and Immunotherapy.
His Chimeric antigen receptor research includes elements of Leukemia, Cell therapy and Antigen, CD19.
In his study, T-cell receptor is strongly linked to Cancer immunotherapy, which falls under the umbrella field of Cancer research.
Carl H. June has researched T cell in several fields, including Ex vivo, CD8, Molecular biology, Cell biology and Cytotoxic T cell.
His research integrates issues of Stem cell and Transplantation in his study of Immunology.
His Immunotherapy study incorporates themes from Tumor microenvironment, Viral vector, Oncology and Lymphoma.
Between 2015 and 2021, his most popular works were:
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia (1540 citations)
- CAR T cell immunotherapy for human cancer (791 citations)
- Cytokine release syndrome in severe COVID-19. (692 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Immune system
His main research concerns Chimeric antigen receptor, Immunotherapy, Cancer research, Antigen and T cell.
He is conducting research in Immunology and Immune system as part of his Chimeric antigen receptor study.
Carl H. June has included themes like Signal transduction, Toxicity and Transplantation in his Immunology study.
His Immunotherapy study combines topics from a wide range of disciplines, such as Antibody, Cell therapy and Oncology.
The Antigen study combines topics in areas such as Receptor, Cytotoxic T cell, Chimeric Antigen Receptor T-Cell Therapy and Lymphoma.
His work carried out in the field of T cell brings together such families of science as Oncolytic adenovirus, Oncolytic virus and Viral vector.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
